Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab for BCG-failure high-risk non–muscle-invasive bladder cancer
ChiCTR2100044439Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in bladder cancer, sponsored by Peking University First Hospital. Primary endpoint: 6-month complete response rate. Started Apr 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2100044439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044439.